Pharming Group's main revenue driver, RUCONEST, has shown a sequential sales rebound, increasing optimism about the company's prospects. However, RUCONEST faces competition from oral treatments, which could complicate revenue stabilization. The analyst believes these challenges are manageable, allowing time for Pharming's other product, Joenja, to grow and improve the business mix. This outlook supports a contrarian buy view on Pharming Group shares based on early positive signs from RUCONEST's performance.
Pharming Group's RUCONEST sales outlook is the subject, with Pluang data providing market context. Of 100 Health-sector US stocks priced on Pluang, 45 rose and 50 fell today. Becton Dickinson and Co traded at USD 184.18 with a 1-day change of +1.21%, and Pluang order activity showed 100% sell as of Sep 30, 2026 19:11 WIB.
Clean Harbors Co-CEO Gerstenberg has sold 2,500 shares of the company. Insider sales like this can indicate personal financial decisions or views on the company’s stock value. Investors often watch such moves for clues about company prospects, though...
Thistle Resources Inc. has acquired the Brunswick East Project Claims, adding 62 units over 13.64 km² adjacent to the Brunswick #12 Mine and its existing Brunswick Antimony Project. This acquisition nearly doubles the project's size to 269 units cove...
Columbia Banking System, parent of Columbia Bank, will release its third quarter 2026 financial results on October 22, 2026, after market close. The company will hold a conference call at 2:00 p.m. PT to discuss the results and recent activities, inc...
In September 2026, US private-sector employment grew by 90,000 jobs, led by education, health care, and leisure sectors, while financial and professional services weakened. Base pay increased 3.2% year-over-year, with job-changers seeing higher raise...
Despite a 13.15% decline in Amazon's stock since early August, Wall Street analysts remain optimistic. Scott Devitt of Rosenblatt Securities raised his 12-month price target to $360, predicting a nearly 46% upside, dismissing concerns about AI disrup...
